Mach-1 Financial Group’s NovoCure NVCR Stock Holding History

Mach-1 Financial Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,646	Closed	-$189K	–	245
2025 Q4	$189K	Buy	+14,646	New	+$188K	0.04%	284
2025 Q3	–	Sell	-18,131	Closed	-$323K	–	361
2025 Q2	$323K	Buy	+18,131	New	+$316K	0.09%	191

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Mach-1 Financial Group's NVCR Position: Q1 2026 in Review

Mach-1 Financial Group sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 14,646 shares — an estimated $189K sold.

Mach-1 Financial Group first reported a position in NVCR in Q2 2025 and held it in 2 quarters. The position peaked at $323K in Q2 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Mach-1 Financial Group reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Mach-1 Financial Group sold 14,646 NovoCure shares in Q1 2026, an estimated $189K.
Mach-1 Financial Group first reported a position in NovoCure in Q2 2025 and held it in 2 quarters.
Mach-1 Financial Group's NovoCure position peaked at $323K in Q2 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Mach-1 Financial Group's 13F filing for Q1 2026, filed 13 May 2026.